ATI Inc.

2 days ago · zacks.com

ATI raises its 2026 outlook for the third time as strong jet engine demand, record AA&S profitability and a $4.3B backlog fuel growth and margin expansion.

3 days ago · marketbeat.com

ATI NYSE: ATI reported third-quarter 2026 results that exceeded its adjusted EBITDA outlook and raised its full-year guidance for the third time this year, citing broad demand across aerospace, defense and specialty-energy markets.

3 days ago · seekingalpha.com

ATI Inc. (ATI) Q3 2026 Earnings Call Transcript

3 days ago · zacks.com

ATI (ATI) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $0.85 per share a year ago.

3 days ago · zacks.com

The headline numbers for ATI (ATI) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

4 days ago · prnewswire.com

Exceeded high-end of Q3 Adjusted EBITDA guide by $13 million Sales increased 26% with growth in all key markets; GAAP-diluted EPS up 76% year-over-year Adjusted EBITDA increased 46% year-over-year, with margin expanding 300 bps to 23.0% Raising full-year 2026 guide by $35 million to $1.195 billion; follows raise of $125 million last quarter Third Quarter 2026 GAAP Financial Results Sales of $1.42 billion, up 26% year-over-year Net income attributable to ATI of $190 million, up 73% year-over-year Earnings per share of $1.37 compared to $0.78 per share in third quarter 2025 Third Quarter 2026 Non-GAAP Financial Information (a) Adjusted net income attributable to ATI(a) of $202 million, up 69% year-over-year Adjusted earnings per share(a) of $1.46, compared to $0.85 per share in third quarter 2025 Adjusted EBITDA(a) of $328 million, an increase of 46% year-over-year Adjusted EBITDA(a) as a percentage of sales of 23.0%, compared to 20.0% in third quarter 2025 Guidance The Company is providing fourth quarter and updated full year 2026 guidance in the table below. Current Guidance Prior Guidance Q4 2026 Full Year 2026 Full Year 2026 Adjusted EBITDA(b) $345M - $355M $1,190M - $1,200M $1,135M - $1,185M Adjusted Earnings Per Share(b) $1.51 - $1.57 $5.17 - $5.23 $4.90 - $5.18 Adjusted Free Cash Flow(b) $550M - $600M $550M - $600M (a) Reconciliations of the reported information under accounting principles generally accepted in the United States (GAAP) to non-GAAP financial measures are included in accompanying financial tables.

4 days ago · zacks.com

ATI, MU and VLO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on October 29th, 2026.

4 days ago · zacks.com

ATI, DK and MPC emerge as momentum picks amid the Anthropic IPO-led rally, combining strong annual gains with recent share-price pullbacks.

5 days ago · zacks.com

ATI heads into Q3 earnings with rising estimates, strong aerospace and defense demand, favorable pricing and operational gains fueling growth expectations.

5 days ago · marketbeat.com

Aclaris Therapeutics NASDAQ: ACRS reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in small studies of atopic dermatitis and asthma. The company said the treatment was well tolerated and produced early clinical and biomarker signals in both indications.